Literature DB >> 22350478

Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis.

Yanming Zhou1, Zhiming Zhang, Yujian Liu, Bin Li, Donghui Xu.   

Abstract

BACKGROUND: Pancreatectomy combined with superior mesenteric vein-portal vein resection (VR) for pancreatic cancer remains a matter of debate. The present study is a meta-analysis of the available evidence.
METHODS: Articles published until end of March 2011, comparing the results of pancreatic resections with VR versus without VR, were searched. Pooled odds ratios (OR) and weighted mean differences (WMD; with 95% Confidence Intervals [95% CI]) were calculated using either the fixed effects model or the random effects model.
RESULTS: Nineteen nonrandomized studies met the inclusion criteria, comprising 2,247 patients. There was no difference in perioperative morbidity (OR: 0.95; 95% CI: 0.74-1.21; P = 0.67), mortality (OR: 1.19; 95% CI: 0.73-1.96; P = 0.48), or 5-year overall survival (OR: 0.57; 95% CI: 0.32-1.02; P = 0.06) between patients with VR and those without VR.
CONCLUSIONS: Pancreatectomy combined with VR resection for pancreatic cancer is justified because it can result in good perioperative outcome and long-term survival comparable to that obtained with standard resection. Owing to the selection bias and low level of clinical evidence available so far, the results should be interpreted with caution.

Entities:  

Mesh:

Year:  2012        PMID: 22350478     DOI: 10.1007/s00268-012-1461-z

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  33 in total

1.  Who benefits from portal vein resection during pancreaticoduodenectomy for pancreatic cancer?

Authors:  B Launois; C Stasik; E Bardaxoglou; B Meunier; J P Campion; L Greco; F Sutherland
Journal:  World J Surg       Date:  1999-09       Impact factor: 3.352

Review 2.  Is pancreaticoduodenectomy with mesentericoportal venous resection safe and worthwhile?

Authors:  P Bachellier; H Nakano; P D Oussoultzoglou; J C Weber; K Boudjema; P D Wolf; D Jaeck
Journal:  Am J Surg       Date:  2001-08       Impact factor: 2.565

3.  Reevaluation of the indications for radical pancreatectomy to treat pancreatic carcinoma: is portal vein infiltration a contraindication?

Authors:  Masaya Kawada; Satoshi Kondo; Shunichi Okushiba; Toshiaki Morikawa; Hiroyuki Katoh
Journal:  Surg Today       Date:  2002       Impact factor: 2.549

4.  Pancreaticoduodenectomy with vascular resection: margin status and survival duration.

Authors:  Jennifer F Tseng; Chandrajit P Raut; Jeffrey E Lee; Peter W T Pisters; Jean-Nicolas Vauthey; Eddie K Abdalla; Henry F Gomez; Charlotte C Sun; Christopher H Crane; Robert A Wolff; Douglas B Evans
Journal:  J Gastrointest Surg       Date:  2004-12       Impact factor: 3.452

5.  Significance of the depth of portal vein wall invasion after curative resection for pancreatic adenocarcinoma.

Authors:  Saburo Fukuda; Elie Oussoultzoglou; Philippe Bachellier; Edoardo Rosso; Hiroshi Nakano; Maxime Audet; Daniel Jaeck
Journal:  Arch Surg       Date:  2007-02

6.  Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma.

Authors:  Kazuaki Shimada; Tsuyoshi Sano; Yoshihiro Sakamoto; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2006-12       Impact factor: 5.344

7.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

8.  Clinical significance of portal invasion by pancreatic head carcinoma.

Authors:  A Nakao; A Harada; T Nonami; T Kaneko; S Inoue; H Takagi
Journal:  Surgery       Date:  1995-01       Impact factor: 3.982

9.  Carcinoma of the periampullary region: who benefits from portal vein resection?

Authors:  J D Roder; H J Stein; J R Siewert
Journal:  Am J Surg       Date:  1996-01       Impact factor: 2.565

10.  Efficacy of venous reconstruction in patients with adenocarcinoma of the pancreatic head.

Authors:  Thomas J Howard; Nicholas Villanustre; Seth A Moore; John DeWitt; Julia LeBlanc; Dean Maglinte; Lee McHenry
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

View more
  54 in total

1.  Surgery for Pancreatic and Periampullary Carcinoma.

Authors:  Abhishek Mitra; Ashwin D'Souza; Mahesh Goel; Shailesh V Shrikhande
Journal:  Indian J Surg       Date:  2015-10-10       Impact factor: 0.656

2.  An Improved Staging System for Locally Advanced Pancreatic Cancer: A Critical Need in the Multidisciplinary Era.

Authors:  Marc W Fromer; Jenci Hawthorne; Prejesh Philips; Michael E Egger; Charles R Scoggins; Kelly M McMasters; Robert C G Martin
Journal:  Ann Surg Oncol       Date:  2021-06-04       Impact factor: 5.344

Review 3.  Anticoagulation policy after venous resection with a pancreatectomy: a systematic review.

Authors:  Manju D Chandrasegaram; Guy D Eslick; Wayne Lee; Mark E Brooke-Smith; Rob Padbury; Christopher S Worthley; John W Chen; John A Windsor
Journal:  HPB (Oxford)       Date:  2013-12-18       Impact factor: 3.647

4.  Neoadjuvant therapy and vascular resection during pancreaticoduodenectomy: shifting the survival curve for patients with locally advanced pancreatic cancer.

Authors:  Irene Epelboym; J DiNorcia; M Winner; M K Lee; J A Lee; B A Schrope; J A Chabot; J D Allendorf
Journal:  World J Surg       Date:  2014-05       Impact factor: 3.352

5.  Intestinal autotransplantation for neoplasms originating in the pancreatic head with involvement of the superior mesenteric artery.

Authors:  Guosheng Wu; Xin Wang; Qingchuan Zhao; Weizhong Wang; Hai Shi; Mian Wang; Jingson Zhang; Zengshan Li; Daiming Fan
Journal:  Langenbecks Arch Surg       Date:  2016-04-23       Impact factor: 3.445

6.  The North American Neuroendocrine Tumor Society Consensus Paper on the Surgical Management of Pancreatic Neuroendocrine Tumors.

Authors:  James R Howe; Nipun B Merchant; Claudius Conrad; Xavier M Keutgen; Julie Hallet; Jeffrey A Drebin; Rebecca M Minter; Terry C Lairmore; Jennifer F Tseng; Herbert J Zeh; Steven K Libutti; Gagandeep Singh; Jeffrey E Lee; Thomas A Hope; Michelle K Kim; Yusuf Menda; Thorvardur R Halfdanarson; Jennifer A Chan; Rodney F Pommier
Journal:  Pancreas       Date:  2020-01       Impact factor: 3.327

7.  Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?

Authors:  Cornelius A Thiels; John R Bergquist; Danuel V Laan; Kristopher P Croome; Rory L Smoot; David M Nagorney; Geoffrey B Thompson; Michael L Kendrick; Michael B Farnell; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

Review 8.  Management of borderline resectable pancreatic cancer.

Authors:  Amit Mahipal; Jessica Frakes; Sarah Hoffe; Richard Kim
Journal:  World J Gastrointest Oncol       Date:  2015-10-15

9.  Does pre-operative chemoradiation for initially unresectable or borderline resectable pancreatic adenocarcinoma increase post-operative morbidity? A case-matched analysis.

Authors:  Raphael L C Araujo; Sébastien Gaujoux; Florence Huguet; Mithat Gonen; Michael I D'Angelica; Ronald P DeMatteo; Yuman Fong; T Peter Kingham; William R Jarnagin; Karyn A Goodman; Peter J Allen
Journal:  HPB (Oxford)       Date:  2013-01-10       Impact factor: 3.647

10.  [Resection for advanced pancreatic cancer following multimodal therapy].

Authors:  J Kleeff; C Stöß; V Yip; W T Knoefel
Journal:  Chirurg       Date:  2016-05       Impact factor: 0.955

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.